Dergiler / Respiratory Case Reports / 2021 / Cilt: 10 - Sayı: 3

Effect of High-Flow Nasal Oxygen Therapy on Tracheobronchial Mucosa in COVID-19 Cases

COVID-19 Olgularında Yüksek Akımlı Nazal Oksijen Tedavisinin Trakeobronşiyal Mukozaya Etkisi

Sayfa
216–219
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Herein, we aim to draw attention to the possible development of muco- sal damage after HFNO, which should be kept in mind during the provision of ventilation support to COVID-19 patients.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:In the ongoing COVID-19 pandemic, several patients have experienced respiratory failure, for which high- flow nasal oxygen therapy (HFNO) is a frequently preferred treatment modality.
📊
Temel Bulgular & Veri:In the present study, three COVID-19 patients being followed up with HFNO in the intensive care unit underwent fiberoptic bronchoscopy, and a burned/wounded mucosa with widespread hyperemia, hyperpigmentation and mu- cosal damage throughout the entire tracheobronchial system mucosa was detected in all cases, the long- term effects of which are unknown.
💡
Sonuç & Katkı:Herein, we aim to draw attention to the possible development of muco- sal damage after HFNO, which should be kept in mind during the provision of ventilation support to COVID-19 patients.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

In the ongoing COVID-19 pandemic, several patients have experienced respiratory failure, for which high- flow nasal oxygen therapy (HFNO) is a frequently preferred treatment modality. In the present study, three COVID-19 patients being followed up with HFNO in the intensive care unit underwent fiberoptic bronchoscopy, and a burned/wounded mucosa with widespread hyperemia, hyperpigmentation and mu- cosal damage throughout the entire tracheobronchial system mucosa was detected in all cases, the long- term effects of which are unknown. Herein, we aim to draw attention to the possible development of muco- sal damage after HFNO, which should be kept in mind during the provision of ventilation support to COVID-19 patients.

Abstract

COVID-19 pandemisinde birçok hastada solunum yetmezliği gelişir ve yüksek akımlı nazal oksijen teda- visi (HFNO) sıklıkla tercih edilen bir tedavi yöntemi- dir. Yoğun bakım ünitesinde HFNO ile izlenen üç COVID-19 hastasına fiberoptik bronkoskopi uygula- dık. Her iki hastada da, trakeobronşiyal sistem muko- zasının tamamında yaygın hiperemi, hiperpigmentas- yon ve mukozal hasar ile birlikte yanmış/hasarlı bir mukoza tespit edildi. Uzun vadeli etkileri bilinmemek- tedir. Bu yazıda HFNO sonrası gelişen mukozal hasa- ra dikkat çekmek istiyoruz. COVID-19 hastalarında ventilasyon desteğine karar verirken bu etkilerin dik- kate alınması uygun olacaktır.

🔖

Bu Makaleye Atıf Yap

ŞENER, M. U., AYDEMİR, S., OZTURK, A. (2021). Effect of High-Flow Nasal Oxygen Therapy on Tracheobronchial Mucosa in COVID-19 Cases. Respiratory Case Reports, Cilt: 10 - Sayı: 3, 216–219. https://ajindex.com/articles/413561

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Preven- tion. JAMA2020; 323:1239-42. [CrossRef] 2. Delclaux C, L'Her E, Alberti C, Mancebo J, Abroug F, Conti G, et al. Treatment of acute hypoxemic nonhyper- capnic respiratory insufficiency with continuous positive airway pressure delivered by a face mask: a randomized controlled trial. JAMA 2000; 284: 2352-60. [CrossRef] 3. Agarwal, A., Basmaji, J., Muttalib, F, Granton D, Cha- udhuri D, Chetan D, et al. High-flow nasal cannula for acute hypoxemic respiratory failure in patients with COVID-19: systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmis- sion. Can J Anaesth 2020; 67, 1217-48. [CrossRef] 4. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med 2020; 46:854-87. [CrossRef] 5. Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med 2015; 372:2185-96. [CrossRef] 6. Wahidi MM, Lamb C, Murgu S, Musani A, Shojaee S, Sachdeva A, et al. American Association for Bronchology and Interventional Pulmonology (AABIP) Statement on the Use of Bronchoscopy and Respiratory Specimen Collec- tion in Patients with Suspected or Confirmed COVID-19 Infection. J Bronchology Interv Pulmonol 2020; 27: e52- e54. [CrossRef] 7. Torrego A, Pajares V, Fernández-Arias C, Vera P, Mancebo J. Bronchoscopy in patients with COVID-19 with invasive mechanical ventilation: a single-center ex- perience. Am J Respir Crit Care Med 2020; 202:284-7. [CrossRef]